440 related articles for article (PubMed ID: 26669603)
1. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
[TBL] [Abstract][Full Text] [Related]
2. CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets.
Kohlmeyer JL; Gordon DJ; Tanas MR; Monga V; Dodd RD; Quelle DE
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344731
[TBL] [Abstract][Full Text] [Related]
3. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
Klein MA
Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
[TBL] [Abstract][Full Text] [Related]
8. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
Balakrishnan A; Vyas A; Deshpande K; Vyas D
World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.
Perez M; Muñoz-Galván S; Jiménez-García MP; Marín JJ; Carnero A
Oncotarget; 2015 Dec; 6(38):40557-74. PubMed ID: 26528855
[TBL] [Abstract][Full Text] [Related]
11. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
[TBL] [Abstract][Full Text] [Related]
12. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinases as therapeutic targets in melanoma.
Miller DM; Flaherty KT
Pigment Cell Melanoma Res; 2014 May; 27(3):351-65. PubMed ID: 24405945
[TBL] [Abstract][Full Text] [Related]
14. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
Bruyère C; Meijer L
Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
[TBL] [Abstract][Full Text] [Related]
15. The history and future of targeting cyclin-dependent kinases in cancer therapy.
Asghar U; Witkiewicz AK; Turner NC; Knudsen ES
Nat Rev Drug Discov; 2015 Feb; 14(2):130-46. PubMed ID: 25633797
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
17. Coming full circle: cyclin-dependent kinases as anti-cancer drug targets.
Fisher RP
Subcell Biochem; 2010; 50():1-15. PubMed ID: 20012574
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.
DiPippo AJ; Patel NK; Barnett CM
Pharmacotherapy; 2016 Jun; 36(6):652-67. PubMed ID: 27087139
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Parua PK; Fisher RP
Nat Chem Biol; 2020 Jul; 16(7):716-724. PubMed ID: 32572259
[TBL] [Abstract][Full Text] [Related]
20. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Kokkinos MI; Thomas H
Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]